Nuvalent CSO exercises options and sells shares
Nuvalent, Inc. Chief Scientific Officer Henry E. Pelish exercised stock options and sold shares in a planned transaction.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Nuvalent, Inc. Chief Scientific Officer Henry E. Pelish exercised stock options and sold shares in a planned transaction. On April 9, 2026, he exercised options to acquire 3,093 shares of Class A common stock at an exercise price of $27.85 per share.
That same day, he sold 2,193 shares at a weighted average price of $104.27 and 900 shares at a weighted average price of $105.00 under a Rule 10b5-1 trading plan adopted on December 11, 2025. After these transactions, he held 65,604 shares of Class A common stock directly.
Insider Trade Summary 10b5-1
Exercise and Sale: 3,093 shares ($237K approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Pelish Henry E.
Role
Chief Scientific Officer
Sold
3,093 shs ($323K)
Approx. gross sale proceeds
$323K
Approx. exercise cost
$86K
Approx. pre-tax spread
$237K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 3,093 | $0.00 | $0.00 |
| Exercise | Class A Common Stock | 3,093 | $27.85 | $86K |
| Sale | Class A Common Stock | 2,193 | $104.27 | $229K |
| Sale | Class A Common Stock | 900 | $105.00 | $95K |
Holdings After Transaction:
Stock Option (Right to Buy) — 8,309 contracts (Direct);
Class A Common Stock — 65,604 shares (Direct)
Footnotes (4)
- F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2025.
- F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.89 to $104.64, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4.
- F3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.97 to $105.08, inclusive.
- F4. The shares underlying this option have vested or shall vest over the four years following January 6, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
Key Figures
Options exercised: 3,093 shares at $27.85
Shares sold (tranche 1): 2,193 shares at $104.27
Shares sold (tranche 2): 900 shares at $105.00
+3 more
6 metrics
Options exercised
3,093 shares at $27.85
Stock option exercise on April 9, 2026
Shares sold (tranche 1)
2,193 shares at $104.27
Weighted average sale price on April 9, 2026
Shares sold (tranche 2)
900 shares at $105.00
Weighted average sale price on April 9, 2026
Post-transaction holdings
65,604 shares
Class A common stock held directly after April 9, 2026
Option expiration
January 6, 2033
Expiration date of exercised stock option
Option vesting schedule
4 years monthly from Jan 6, 2023
Vesting of shares underlying the option
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), vesting
4 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.89 to $104.64, inclusive."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
vesting financial
"The shares underlying this option have vested or shall vest over the four years following January 6, 2023 in equal monthly installments, subject to continued service."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Nuvalent (NUVL) executive Henry E. Pelish do in this Form 4 filing?
Henry E. Pelish, Nuvalent’s Chief Scientific Officer, exercised stock options and sold shares on April 9, 2026. He acquired 3,093 Class A common shares via option exercise and sold 3,093 shares in open-market transactions disclosed in this filing.
What stock options did Henry E. Pelish exercise in Nuvalent (NUVL)?
Pelish exercised options for 3,093 shares of Nuvalent Class A common stock at an exercise price of $27.85 per share. The underlying option, expiring January 6, 2033, vests in equal monthly installments over four years starting January 6, 2023.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates